Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Yale University
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02085070 | https://clinicaltrials.gov/study/NCT07458113 | https://clinicaltrials.gov/study/NCT07193160 | https://clinicaltrials.gov/study/NCT07329322 | https://clinicaltrials.gov/study/NCT07343453 | https://clinicaltrials.gov/study/NCT06483334 | https://clinicaltrials.gov/study/NCT06637423
Assets
Linked programs
- MK-3475: Watchlist Signal (2/5)
- Sacituzumab tirumotecan: Watchlist Signal (2/5)